Annovis Bio Inc. (ANVS) announces patients treated with ANVS401 for 25 days showed statistically significant cognitive improvement as measured by the Alzheimer’s Disease Scale
This is the first double-blind, placebo-controlled study that shows cognitive improvements in AD patients as measured by ADAS-Cog and functional improvements in PD patients as measured by the Unified Parkinson's Disease Rating Scale (UPDRS)
Anything which appears to show benefits to actual human beings and not just in fruit flies, worms, mice, rats, or monkeys is exciting to me. Thanks for sharing!
it was double-blinded, but it was not really placebo-controlled. I was told that the dose I received might be 5, 10, 20, or 40 mg of Posiphen (Synonyms: ANVS-401, (+)-phenserine, Posiphen tartrate .) Maybe they consider a 5 mg dose as a placebo. alzforum.org/therapeutics/p...
I'm in a positive mode today and speculate that it might be a recovery symptom from the treatment. If the neural pathways are cleaned up, it might be that the signals to (and feedback from) the muscles become stronger. So it may take some time for the CNS to adapt . I would have focused on balance training for a period to see if improves.
"it was double-blinded, but it was not really placebo-controlled. I was told that the dose I received might be 5, 10, 20, or 40 mg of Posiphen"
Thanks for sharing. Always interesting to hear first hand info from a participant.
I wonder if it could be that you were not among the first 14 PD, but in the second group of 40 to investigate optimal dose?
"The first 14 PD plus 14 AD patients, whose data are reported here, have finished treatment and their biomarkers are being measured. Recently, Annovis Bio reported the results of the measurement of inflammation in the first 14 PD patients using four biomarkers. The last 40 patients are being treated with different doses to determine the optimal dose. The study compares, in both patient populations, how nerve cells die by measuring all the steps in the toxic cascade leading to nerve cell death and how ANVS401 reverses the toxic cascade and recovers normal brain and body function."
"This interim analysis includes data from the first 14 Parkinson’s patients who have completed treatment; nine were given ANVS401, and five received placebo."
I would like to participate in the next trial, but very unlikely will be accepted, plus I had to travel to another town - 3 hours flight - three (3) times during one month
It seems to me that if you participate in a trial you should be allowed to continue with the best guess of the proper dosage for as long as you like. That would provide multiple long term single participant open label trials to gather more info (and it just seems right).
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.